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The TNM tumour classification system together with tumour site,
type, grade and thickness, are all used to predict which patients are
at risk of developing local or distant recurrence and plan adjuvant
therapy (Spiro et al, 1986; Anneroth et al, 1987; Langdon and
Henk 1995). However, despite taking into account all the available
prognostic information when making crucial decisions about treat-
ment, many patients develop local or distant recurrence. This
failure is due to the inability to detect small numbers of malignant
cells which remain in the body after treatment and the requirement
to take into account information about tumour biology in addition
to the conventional clinical and histologic prognostic criteria.
Solid tumour formation requires multiple mutational events.
Recent studies examining oral squamous cell carcinomas (SCC)
have identified frequent deletion or mutation affecting one allele
of the p53, Rb and DCC tumour suppressor genes (Largey et al,
1993; Lee et al 1994; Min et al, 1994; Brennan et al, 1995; Rowley
et al, 1995; Maestro et al, 1996; Nylander et al, 1996). However,
few studies have interrogated both copies of these sequences
although homozygous deletions of p16 have been reported (Cairns
et al, 1995). Several other chromosomal areas that are likely to
harbour other suppressor sequences likely to play a role in the
development of these tumours have been identified at chromo-
somes 3p, 8p and 9p by cytogenetics and loss of heterozygosity
studies (El-Naggar et al, 1993; Field et al, 1994; Kiaris et al, 1994;
Partridge et al, 1994, 1996; van der Reit et al, 1994; van Dyke et
al, 1994; Wu et al, 1994; Califarno et al, 1996; Ishwad
et al, 1996); however, the critical sequences within these candidate
suppressor areas are currently unknown. Although only prelimi-
nary data about the genetic aberrations associated with tumori-
genesis is available, a genetic model has been proposed (Califarno
et al, 1996) with specific gene alterations indicated as early (AI at
3p, 9p21), intermediate (AI at 11q, 14q, 14q) and late events (AI at
8p, 4q). Study of head and neck (Field et al, 1994; El-Naggar
et al, 1995; Partridge et al, 1996; Lee et al, 1997; Kelker et al,
1996; Lydiatt et al, 1998) and of other solid tumours (Kerangueven
et al, 1997) has suggested that AI at specific chromosomal regions,
and the number of aberrations detected, can help predict outcome
(Vogelstein et al, 1989; Field et al, 1995). This new knowledge
means that it is now possible to apply molecular studies to tumours
in vitro and incorporate information about the key genetic abnor-
malities for each tumour into conventional staging systems. This
will enable clinicians to identify a tumour’s potential for progres-
sion more accurately and use this information to modify existing
treatment protocols to improve clinical course and outcome.
In this study we have looked for allelic imbalance (AI) at 19 loci
at chromosomes 3p, 8p21–23, 9p13–21, 9q22, 13q14.2 and within
the p53, Rb and DCC tumour suppressor genes since these
sequences have all been implicated in the pathogenesis of head
and neck and oral SCC (see references cited above). We have used
more markers at 3p since alterations here are the most frequent
genetic change in oral cancer reported to date and the available
evidence suggests that this chromosome arm may harbour multiple
tumour suppressors (Field et al, 1994; Partridge et al, 1994, 1996;
Wu et al, 1994; Ishwad et al, 1996). We have determined the
prevalence of AI at these key loci and summarized the data as a
fractional allelic loss (FAL; Vogelstein et al, 1989) score for each
individual patient and looked for commonly recurring patterns of
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FOM: floor of mouth; V: verruccous; W: well-differentiated; M: moderately differentiated; P: poorly differentiated; A: alive; D: dead; DD: died of disease;
DC: died of other causes; NA: data not available; Y: yes; N: no; FAL: fractional allelic loss.  = allelic imbalance; n n = retention of heterozygosity;
= microsatellite instability or non-informative;   = not done. 
Table 1 Clinicopathological features and risk factors for oral SCC examined and alleleo-typing results of tumours examinedAI at key loci in oral cancer 1823
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AI. In addition we have determined whether specific patterns of
genetic aberration can predict risk of loco-regional recurrence,
identify patients with poor outcome and provide additional prog-
nostic information.
MATERIALS AND METHODS
Forty-eight primary oral SCC were snap frozen in liquid nitrogen
immediately after surgical resection and stored at –70°C. Venous
blood was stored in tubes with NaCl–EDTA and kept at –20°C until
required. Approval for this project was granted by the Ethical
Committee at Kings College Hospital. Patients were staged clinically
according to Union Internationale Contrele Cancer (UICC) TNM
Classification of Malignant Tumours criteria (Hermanek and Sobin,
1987) and restaged following histopathological examination of the
resection specimen if the initial nodal status was incorrect. The
median follow-up time of the 20 living patients in this study was 49
months (range 28–166 months). The clinicopathological features and
risk factors for the tumours studied are summarized in Table 1.
Ten-micrometer frozen sections were mounted onto microscope
slides and stained with toluidine blue for microdissection. Samples
were digested in 100 ml of lysis buffer (Partridge et al, 1996).
Genomic DNA was extracted from venous blood by lysis with
Triton-X100. Three polymorphic markers for polymerase chain
reaction-restriction fragment length polymorphism (PCR-RFLP)
analysis and 13 microsatellite markers, which show frequent loss
of heterozygosity when head and neck and oral SCC are examined,
were selected for analysis. To examine loss of heterozygosity
(LOH) at THRB, D3S686, D3S32 and D3S30 by RFLP analysis of
normal and tumour samples was performed using two rounds of
PCR analysis (Partridge et al, 1996). Multiple restriction enzymes
were used to maximize the number of informative patients for the
THRB locus. Amplification was performed in a volume of 50 ml
containing 5 ml of DNA solution, or 50 ng of genomic DNA.
Fifteen microliters of the product were digested with 10 units of
the appropriate restriction enzyme. The digests were fractionated
on 4% agarose gels, stained with ethidium bromide and
photographed.
PCR primers for the polymorphic microsatellite markers were
obtained from Research Genetics, Huntsville, USA or synthesized
locally. One of the primers was end-labelled with [g32P]ATP and
PCR products were generated from standard reactions. Products
were separated by gel electrophoresis in denaturing 6% poly-
acrylamide–7 M urea and autoradiographed overnight. Labelled
pBR322 was included as a sequencing ladder to facilitate sizing of
the alleles.
Cases were scored by visual inspection of band patterns and
considered to show AI if the ratio of the two alleles in the tumour
was 50% less than that detected for the normal sample. Novel
microsatellite alleles were identified by the presence of bands that
were absent in the normal sample, and these cases scored as
showing microsatellite instability and excluded from the informa-
tive cases. The FAL score was calculated for each patient
by dividing the number of loci showing AI by the number of infor-
mative loci.
The relationship between two ordinal variables, or two quantita-
tive variables, was investigated using Spearman’s rank correlation.
Ordinal or quantitative variables were compared between different
categories defined by a nominal variable by the Kruskal–Wallis
test (for three or more groups) and the Mann–Whitney U-test (for
two groups). If three or more groups were compared, the Mann-
Whitney U-test was only applied if the Kruskal–Wallis test was
significant. The c2 test was used to compare proportions, except in
the case of a 2 ´ 2 table with any expected value less than 5; in this
case Fisher’s exact test was employed. Yates’ correlation was
applied when analysing 2 ´ 2 tables using the c2 test. To investi-
gate the relationship between risk factors (tobacco intake and
alcohol consumption) and FAL score, patients were divided into
groups. These were: non-smokers, 1–25 cigarettes a day and
> 25 cigarettes a day; no alcohol, 1–4 units a day, 5–9 units a day
and > 10 units a day. Survival curves were calculated using the
Kaplan–Meier product-limit method and compared by the log-
rank test. Hazard ratios, an ‘average’ relative event rate over the
follow-up period, were calculated using Cox’s regression (Cox,
1972). For example, if every month there was one death in a group
and two deaths in another, then the hazard ratio for the second
group relative to the first would be 2.
RESULTS
Relationship between AI and clinicopathological
features of the tumours examined
The highest frequency of AI was detected for markers at D3S1562
(47%), the interferon alpha (INF-a) locus at 9p21 (37%), D9S43
at 9p13 (38%), D9S177 at 9q22 (37%), p53 (36%) and DCC
(34%). Overall 45/48 (94%) of the lesions examined showed AI at
one or more of the chromosomal loci studied. The data are summa-
rized; Table 1 and Figure 1 show representative examples of
the microsatellites used. No relation was observed between the
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Figure 1 Microsatellite alterations in DNA from tumour (T). The loci and
case numbers are indicated above the gel lanes. Normal leucocyte DNA is
indicated by N. The arrows highlight the altered allelesmedian FAL score and the site of the tumour. Lesions examined
developed on the floor of the mouth (13), alveolus (12), on the
buccal mucosa (9), tongue (11) and at other sites (4). The median
FAL at these four sites was 0.37, 0.30, 0.27, 0.18 and 0.20 respec-
tively. Similarly, no relationship was found between exposure to
risk factors (smoking and alcohol consumption), higher tumour
grade and the median FAL.
Relationship between FAL score and outcome
The median FAL was 0.29 (range 0–0.84). However, the FAL
score for patients presenting with stage 4 tumours was much
higher, median 0.50 (range 0.15–0.84), than the score for patients
presenting with stage 1–3 tumours, median 0.27 (range 0–0.80,
P = 0.01). To investigate the relationship between the frequency of
genetic aberrations and overall survival, patients were divided into
three approximately equally sized groups on the basis of the FAL
score. Figure 2 shows the survival probability for the three groups
and reveals a significant association between the FAL score and
overall survival. The relative hazard ratios for survival analysis in
the low, intermediate and high FAL score groups were 1, 5.37 and
8.36, respectively (P < 0.0002), using the group with the lowest
level of AI as the reference group. Multivariate analysis using
Cox’s regression, indicates that this relationship is independent of
stage. (The P-value was 0.0006 when allowing for stage.) A
significant relationship was also detected between the FAL score
and development of loco-regional recurrence (see Figure 3).
Univariate analysis was performed to assess whether AI at
sequences within the p53, Rb and DCC tumour suppressor genes,
or at one or more loci within the candidate suppressor areas, were
associated with poor prognosis. (The results for several adjacent
loci at the same chromosomal region, which together form these
candidate tumour suppressor gene areas, were combined to reduce
multiple significance testing, see Table 2.) However, as ten or
more patients were non-informative for all but the THRB locus,
tests of the prognostic significance of AI are inevitably weak.
Nevertheless, AI at one or more loci within the 3p24–26 region,
3p21, 3p13, 9p21 and within the THRB and DCC genes were all
associated with reduced survival (P < 0.1, Table 2).
AI within the three chromosomal regions investigated at 3p
that were associated with poor prognosis (P < 0.1 on univariate
analysis), were examined to determine whether they were of inde-
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Table 2 Relationship between outcome and Al at the chromosomal loci tested
Chromosomal Loci examined Number of cases HR for survival P-value
region non-informative
3p24–26 D3S192, THRB 4 4.21 0.0002
3p21 D3S32, D3S1241, D3S1562 0 1.99 0.07
3p13 D3S1296. D3S1562, D3S30 2 2.52 0.02
8p12–23 D8S261, D8S298, Ank-1 5 1.25 ns
9p21 D9S162, INFa, D9S171 1 2.65 0.01
9p13 D9S43 9 1.56 ns
9q22.3 D9S177 14 1.78 ns
13q14.2 Rb 7 1.16 ns
17p13.1 p53 12 1.85 ns
18q21.1 DCC 13 2.39 0.05
HR = hazard ratio.
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Figure 2 Kaplan–Meier analysis of patients with oral squamous cell
tumours. Patients were divided into three groups according to the FAL score
and compared. Bars on the survival curves indicated patients alive at the
indicated time
Figure 3 Probability of developing local recurrence for the three FAL score
groupspendent prognostic significance. AI at 3p24–26, 3p13 and 9p21
were found to predict poor prognosis independently, of each other
with hazard ratios of 3.93, 2.60 and 2.48 (P = 0.002, P = 0.03 and
P = 0.03 respectively). This implies that patients with AI at all of
these regions at 3p would have an approximately 25 times increase
in their mortality rate relative to a patient showing retention of
heterozygosity at the loci tested. AI at all of these three key
chromosomal regions was also found to be a better predictor of
outcome than TNM stage, which no longer reached statistical
significance when the effect of aberrations at these three regions
was taken into account. AI at these three chromosomal regions was
also found to predict prognosis independent of the FAL score;
however, FAL was still significant once these loci had been
allowed for, suggesting that aberrations affecting other chromo-
somal regions may still be important.
Commonly occurring patterns of AI
The data were analysed using the c2 test to determine whether AI
at pairs of loci occurred more frequently than might be expected
by chance. There were 171 possible pairs of loci for which associ-
ations could be tested. Approximately nine significant pairings
would be expected to be present by chance at the 5% level and 14
were actually found. Two of these were significant at P = 0.001, AI
at D3S686 and D9S171 and D9S162 and INF-a. A further three
associations were significant at P = 0.01 and formed a triplet
comprising D3S1296, D9S43 and DCC.
Further analysis was performed to see whether AI at loci at
different chromosomal arms, which frequently occur together, was
associated with poor survival. Twenty-six cases were assessable
at both D3S686 and D9S171, and 21 cases at D3S1296, DCC and
D9S43. When cases with AI at D3S686 and D9S171 were
compared with those that showed retention of heterozygosity
(ROH) using Cox’s regression, AI involving this doublet was
found to be associated with a poorer prognosis (P = 0.02) and to be
a better predictor of outcome than the FAL score or TNM stage. In
addition, AI at D3S1296 and DCC, D3S1296 and D9S43, and
DCC and D9S43 were all found to be associated with poor
prognosis (P < 0.001) and to predict prognosis more accurately
than the FAL score or TNM stage.
DISCUSSION
AI at all loci tested was detected for patients with early stage 1 and
2 tumours and for advanced stage 3 and 4 lesions. A variety of
different patterns of AI were seen for tumours of the same TNM
stage. Although these aberrations represent only a fraction of the
total number of abnormalities likely to be present in each cancer,
the different profiles for each tumour reveal the potential
complexity of the molecular process involved in head and neck
tumorigenesis and provide a partial explanation for the different
biological behaviour that tumours classified as being of the same
TNM stage may exhibit.
The percentage AI at the different chromosomal segments
demonstrates large variation amongst the published series for head
and neck (El-Naggar et al, 1993; Ah-See et al, 1994; Nawroz et al,
1994; Field et al, 1996; Partridge et al, 1996). The percentage AI
found for the present study of oral SCC are typically lower than
those reported for head and neck SCC. However, since the various
studies have applied different markers, with different levels of
informativeness, this precludes the conclusion that these differ-
ences reflect distinct mechanisms of tumour development.
Summarizing the number of loci showing AI as a FAL score
has identified a subgroup of patients likely to develop loco-
regional recurrence (P = 0.02, Figure 2) and show reduced survival
(P = 0.0002, Figure 3), thus providing new prognostic information.
These findings extend the report by Field et al, (1996), indicating
that FAL greater than median value correlated with poor survival
(P < 0.19). However, these authors also found a significant rela-
tionship between FAL score and the presence of lymph nodes at
presentation, an association not confirmed in the present study.
These differences are likely to reflect inclusion of cases previously
treated by radiotherapy in the study reported by Field et al (1966).
The FAL score was not related to tobacco usage and alcohol
consumption. Lack of correlation between these risk factors and
AI at chromosome 3p and 9p has been reported previously for oral
SCC (Partridge et al, 1994) and pre-invasive lesions (Mao et al,
1996). This suggests that other aetiological agents, environmental
factors and inherited factors, which have yet to be determined,
often exert their effects via the same genetic mechanisms.
Univariate analysis revealed that AI at 3p24–26, 3p21, 3p13 and
9p21 and DCC predict poor prognosis. However, AI at 3p24–26,
3p13 and 9p21 were found to predict prognosis independently of
each other with hazard ratios of 3.93, 2.60 and 2.48. This indicates
that patients with AI at each of these regions have an approxi-
mately 25 times increase in their mortality rate relative to a patient
showing ROH at these loci. AI at these three key chromosomal
regions was also found to be a better predictor of outcome than
TNM stage, which no longer reached statistical significance when
the effect of aberrations at these three regions was taken into
account.
AI at specific pairs of loci, namely D3S686 and D9S171,
D3S1296 and D9S43, D3S1296 and DCC, and D9S43 and DCC,
also provided additional prognostic information. AI at these
doublets occurred more frequently than would be expected by
chance and was associated with reduced survival. For example, AI
involving the doublets D3S686 and D9S171, and D9S162 and
INF-a (adjacent loci at 9p21), and at least two of D3S1296, DCC
and D9S43, was found to be a better predictor of prognosis than
the FAL score or TNM stage. This suggests that these chromo-
somal regions must contain, or be close to, sequences that, when
both are disrupted, have a very adverse effect on outcome for this
group of patients.
At present, the identity of the sequences at these key chromo-
somal loci is largely unknown. The p16 gene, a cyclin-dependent
kinase inhibitor, is a well-defined tumour suppressor gene at 9p21.
This sequence lies centromeric to D9S162 and INF-a, two
markers found to be significantly associated with poor prognosis
in the present study. However, the pattern of AI found at 9p when
a series of overlapping markers is used to study upper aerodiges-
tive tract tumours, suggests the existence of additional tumour
suppressor genes centromeric (Kim et al, 1997; Weist et al, 1997)
and telomeric (Neville et al, 1995; Kim et al, 1997) to p16. The
high frequency of AI at the D9S43 marker, which lies centromeric
to p16, in the present study strengthens the notion that this chro-
mosomal region harbours additional tumour suppressor sequences
for this tumour type.
AI at 3p21.33, the location of the D3S686 marker, has been
extensively studied and several sequences have been isolated from
deletions involving this region (reviewed by Todd et al, 1997). The
AI at key loci in oral cancer 1825
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been identified as the targets for deletion in lung cancer cell lines
showing homozygous deletions at 3p21.33 (Sekido et al, 1996).
These sequences are widely expressed in adult tissues, which
suggests that they may serve functions other than nerve cone guid-
ance, perhaps influencing contact inhibition or differentiation in
epithelia. However, many other sequences have been identified as
possible targets for deletion within this gene-rich area (Todd et al,
1996) and the role of these sequences in head and neck SCC is
currently unknown. The 3p13 region, at which the D3S1296
marker resides, contains the U2020 small cell lung cancer deletion
and lies telomeric to the 3p14.3 fragile site. This region is also
likely to harbour a tumour suppressor gene for oral cancer.
Several breakpoints involving 18q have also been reported for
head and neck SCC suggesting the possible involvement of more
than one gene at this chromosomal arm. The DCC, DPC4 and
MADR2 genes (Frank et al, 1997) have all been implicated as
putative tumour suppressor genes at 18q21. Although AI
involving DCC occurs frequently in solid tumours this observation
does not establish DCC as a tumour suppressor gene and the low
frequency of AI at DPC4 (Kim et al, 1996) suggests that LOH at
this region may be associated with other tumour suppressor genes.
Typically, tumour suppressor genes act in a recessive manner
such that loss of both alleles is required to inactivate these
sequences. However, the findings from this study reveal that loss
of one copy of a tumour suppressor gene or a candidate suppressor
area provides additional prognostic information. At present the
status of the other allele of the p16, p53, DCC and Rb tumour
suppressor sequences investigated in this study is unknown.
However, several reports have shown that AI within a known
tumour suppressor sequence can occur without mutation of the
other copy (Wagata et al, 1993; Lee et al, 1994; Li et al, 1995;
Maestro et al, 1996). There are also other ways of inactivating
tumour suppressor genes; for example, silenced gene transcription
associated with hypermethylation (Jones et al, 1990), or associa-
tion with oncogenic viral proteins (Min et al, 1994). Nevertheless,
the finding that information about aberrations affecting just one
copy of a tumour suppressor gene sequences does have prognostic
significance, suggests that so-called dosage effects, where levels
of the gene product are altered sufficiently to disrupt normal
growth control processes (Kemp et al, 1993), have significant
biological consequences and may be more important than previ-
ously realized.
These data reveal that summarizing the level of genetic damage
as a FAL score, as well as screening tumours for AI at key chro-
mosomal loci, and pairs of loci can provide new prognostic infor-
mation. This suggests that, as more of the critical aberrations
associated with tumorigenesis are identified, it will be possible to
develop a molecular staging system, which will identify patients
with an unfavourable genetic and clinical profile who are likely to
benefit from aggressive treatment when they first present at the
clinic. However, many studies have evaluated single, or small
groups of markers for head and neck cancer patients, and as a
result of this clinicians are now faced with a daunting list of publi-
cations describing new prognostic markers. At this stage careful
consideration must be given to how, and if, this information, which
is often obtained following analysis of very small numbers of
patients, can be used to influence treatment decisions. What is
clear is that, as our knowledge of the complexity of the events in
tumorigenesis has increased, multiple markers will be needed to
give representative information about any given tumour. At this
stage large numbers of cases need to be examined and new prog-
nostic markers validated by testing a different geographic popula-
tion before this information can be used to influence decisions
about treatment.
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